Daniel J. Felmlee, Thomas F. Baumert  Journal of Hepatology 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Laurent Mailly, Mirjam B. Zeisel, Thomas F. Baumert 
Volume 46, Issue 3, Pages (March 2007)
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
Inflammasomes in liver diseases
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
Volume 59, Issue 5, Pages (November 2013)
John W. Bloom, MD  Journal of Allergy and Clinical Immunology 
Hepatic CD141+IFNλ+ DC subset: One against all?
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
Mirjam B. Zeisel, Isabel Fofana, Samira Fafi-Kremer, Thomas F. Baumert 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 47, Issue 1, Pages (July 2007)
Volume 52, Issue 3, Pages (March 2010)
NS5A inhibitors in the treatment of hepatitis C
Innate signals in mucosal immunoglobulin class switching
Immigration and viral hepatitis
Toll-like receptors in Borrelia burgdorferi-induced inflammation
Omega 3 – Omega 6: What is right for the liver?
Endoplasmic reticulum stress in liver disease
Hepatitis C virus entry and glucocorticosteroids
Mechanisms of HBV-related hepatocarcinogenesis
Methed-Up FOXOs Can't In-Akt-ivate
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Volume 61, Issue 2, Pages (August 2014)
Hepatitis C core protein – The “core” of immune deception?
Volume 59, Issue 5, Pages (November 2013)
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Biomarkers of liver cell death
RNAi – A powerful tool to unravel hepatitis C virus–host interactions within the infectious life cycle  Joachim Lupberger, Laurent Brino, Thomas F. Baumert 
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Hepatitis C virus–cell interactions and their role in pathogenesis
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Advancing hepatitis B virus entry inhibitors
Autophagy in the liver Journal of Hepatology
Jo-Ellen Murphy, Caroline Robert, Thomas S. Kupper 
Connecting Mitochondria and Innate Immunity
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…
Volume 50, Issue 4, Pages (April 2009)
Death receptor-mediated apoptosis and the liver
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
The Met1-Linked Ubiquitin Machinery: Emerging Themes of (De)regulation
Volume 61, Issue 1, Pages S79-S90 (November 2014)
miR-122 – A key factor and therapeutic target in liver disease
Immigration and viral hepatitis
Treatment failure in hepatitis C: Mechanisms of non-response
The AhR–Nrf2 Pathway in Keratinocytes: On the Road to Chemoprevention?
Manfred Fliegauf, PhD, Bodo Grimbacher, MD 
Volume 64, Issue 6, Pages (June 2016)
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
Tetsuo Takehara, Norio Hayashi 
Pathogenesis of cholestatic hepatitis C
Increased understanding leads to increased complexity: Molecular mechanisms of pulmonary arterial hypertension  Victor A. Ferraris, MD, PhD  The Journal.
Chimeric mouse model of hepatitis B virus infection
Shared Principles in NF-κB Signaling
Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments  László Maródi, MD, PhD, Jean-Laurent.
Treating myocardial ischemia-reperfusion injury by targeting endothelial cell transcription  Edward M Boyle, MD, Timothy G Canty, MD, Elizabeth N Morgan,
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Philippe Metz, Antje Reuter, Silke Bender, Ralf Bartenschlager 
Mirjam B. Zeisel, Marine Turek, Thomas F. Baumert 
Nathalie Ganne-Carrié, Pierre Nahon  Journal of Hepatology 
Elien Van Nuffel, Anja Schmitt, Inna S
Presentation transcript:

Hepatitis C virus co-opts innate immunity component for lipid droplet formation  Daniel J. Felmlee, Thomas F. Baumert  Journal of Hepatology  Volume 59, Issue 5, Pages 1118-1120 (November 2013) DOI: 10.1016/j.jhep.2013.07.002 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 HCV co-opts IKK-α to promote HCV assembly. The canonical nuclear factor (NF)-κB pathway involves an NF-κB family member bound to an inhibitor of NF-κB (IκB) that retains the complex in the cytoplasm. Upon IκB phosphorylation from the IκB kinase (IKK) complex, IκB is degraded, liberating NF-κB to translocate to the nucleus and to regulate genes involved in innate immunity [5]. The IKK complex consists of NF-κB essential modifier (NEMO), and IKK catalytic units IKK-α and IKK-β. The 3′ untranslated region (UTR) contains a pathogen-associated molecular pattern (PAMP) that forms a complex with DDX3X, activating IKK-α. Active IKK-α and CREB binding protein (CBP/p300) subsequently bind the promoter and transcriptionally activate sterol response element binding protein 1 (SREBP-1). SREBP-1 transcriptionally drives lipogenic genes resulting in an accumulation of lipid droplets [6]. HCV uses lipid droplets as platforms for assembly [1], and all of the factors involved in this IKK-α mediated pathway are important for the HCV life cycle [3]. Journal of Hepatology 2013 59, 1118-1120DOI: (10.1016/j.jhep.2013.07.002) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions